Montero, PaulaSanz, CeliaPérez Fidalgo, J. A.Pérez Leal, MartínMilara, JavierCortijo, Julio2026-01-192026-01-192024Montero, P., Sanz, C., Pérez‐Fidalgo, J. A., Pérez‐Leal, M., Milara, J., & Cortijo, J. (2024). Paclitaxel alters melanogenesis and causes pigmentation in the skin of gynecological cancer patients. Fundamental & Clinical Pharmacology, 38(1), 183-191. https://doi.org/10.1111/fcp.129430767-3981https://hdl.handle.net/11268/16743Paclitaxel (PTX) is a microtubule-stabilizing antineoplasticthat has been shown to damage healthy tissues like the skin. Hyperpigmen-tation can be found among the adverse effects caused by PTX, but the liter-ature is limited and the mechanisms driving PTX-induced pigmentaryalterations are unknown. This study aimed to describe the pigmentary alterations causedby PTX and to determine the effects of PTX on melanocytes. The results suggest that PTX alters pigmentation in patientswith no clinically visible manifestations, and these alterations might bedriven by its capacity to stimulate melanogenesis on melanocytes throughthe MITF activation pathway.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/journal article10.1111/fcp.12943open accessCiencias médicasFarmacologíaEnfermedad de la pielGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 5: Achieve gender equality and empower all women and girlsGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovation